Early-stage biotechs with limited funds must balance the need for quick data with building a solid IND package. The solution is to run two tracks in parallel: one for immediate R&D experiments and another dedicated to the methodical, long-term planning required for regulatory submission.

Many effective drugs that are already developed will not reach patients for years because the clinical trial system is the primary bottleneck. This delay is due to logistical and structural inefficiencies in testing, not a lack of scientific discovery.

To avoid wasting limited funds, startups should first validate their target product profile with regulators and investors. This 'end in mind' approach allows them to work backward, defining the exact data packages needed and prioritizing only the experiments that directly contribute to that goal.

Instead of creating a massive risk register, identify the core assumptions your product relies on. Prioritize testing the one that, if proven wrong, would cause your product to fail the fastest. This focuses effort on existential threats over minor issues.

A major source of unproductivity in drug development isn't the time spent reaching a clinical milestone. Instead, it's the 'white space' after data is received—the delay in analyzing results and making a firm go/no-go decision, which stalls the entire program.

Our ability to generate and test therapeutic hypotheses in silico is rapidly outpacing the slow, expensive conventional clinical trial system. Without regulatory reform, the pipeline of promising drugs will remain stuck, preventing breakthroughs from reaching patients. The science is solvable; the system is not.

In biotech, early data is often ambiguous. Instead of judging programs on potential, leaders must prioritize based on the time and capital required to reach a clear 'yes' or 'no' outcome. Indefinite 'gray zone' projects drain resources that could fund a winner.

The FDA's traditional focus on risk avoidance overlooks the inherent risk of delay. Unnecessary bureaucratic steps, like months of animal trials, prevent dying patients from accessing potentially life-saving treatments. The cost of inaction is measured in lives lost.

Scientists often design trials to answer every possible academic question, which adds complexity and patient burden. Drug development trials should be ruthlessly focused on two things only: safety and efficacy. All other extraneous research can wait for post-approval studies.